AARTI DRUGS Financial Statement Analysis
|
||
|
The Revenues of AARTI DRUGS have increased by 9.14% YoY .
The Earnings Per Share (EPS) of AARTI DRUGS has increased by 3.84 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
AARTI DRUGS Last 5 Annual Financial Results
[BOM: 524348|NSE : AARTIDRUGS]
| Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹2,716 Cr | ₹2,489 Cr | ₹2,155 Cr | ₹1,806 Cr | ₹1,561 Cr |
| Expenses | ₹2,407 Cr | ₹2,156 Cr | ₹1,714 Cr | ₹1,541 Cr | ₹1,350 Cr |
| Operating Profit (Excl OI) | ₹309 Cr | ₹333 Cr | ₹440 Cr | ₹266 Cr | ₹211 Cr |
| Other Income | ₹2.19 Cr | ₹11 Cr | ₹4.53 Cr | ₹1.48 Cr | ₹2.41 Cr |
| Interest | ₹37 Cr | ₹24 Cr | ₹26 Cr | ₹37 Cr | ₹44 Cr |
| Depreciation | ₹50 Cr | ₹50 Cr | ₹50 Cr | ₹49 Cr | ₹43 Cr |
| Profit Before Tax | ₹224 Cr | ₹270 Cr | ₹369 Cr | ₹185 Cr | ₹131 Cr |
| Profit After Tax | ₹166 Cr | ₹205 Cr | ₹280 Cr | ₹141 Cr | ₹90 Cr |
| Consolidated Net Profit | ₹166 Cr | ₹205 Cr | ₹280 Cr | ₹141 Cr | ₹90 Cr |
| Earnings Per Share (Rs) | ₹18.65 | ₹17.96 | ₹22.14 | ₹30.09 | ₹60.69 |
| PAT Margin (%) | 6.79 | 6.12 | 8.24 | 13.01 | 7.83 |
| ROE(%) | 13.87 | 14.93 | 21.03 | 35.81 | 23.65 |
| ROCE(%) | 15.01 | 15.49 | 20.75 | 34.52 | 21.39 |
| Total Debt/Equity(x) | 0.44 | 0.51 | 0.52 | 0.38 | 0.58 |
Key Financials |
||
| Market Cap | : | ₹ 3,817.7 Cr |
| Revenue (TTM) | : | ₹ 2,387.0 Cr |
| Net Profit(TTM) | : | ₹ 168.1 Cr |
| EPS (TTM) | : | ₹ 18.4 |
| P/E (TTM) | : | 22.7 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| AARTI DRUGS | 17.6% | 25.6% | -14.9% |
| SUN PHARMACEUTICAL INDUSTRIES | -4.9% | 2.1% | 15.5% |
| DIVIS LABORATORIES | -2.2% | 9.3% | 50.5% |
| CIPLA | -4.2% | 4.5% | 4.5% |
| TORRENT PHARMACEUTICALS | -4.4% | -4.5% | 17.2% |
| DR REDDYS LABORATORIES | -1.4% | 4.2% | -8.8% |
| MANKIND PHARMA | -0.1% | -1.5% | 6.6% |
| ZYDUS LIFESCIENCES | -1.6% | 1.3% | -14.6% |
| LUPIN | -2.4% | 3.4% | 19.9% |
AARTI DRUGS Revenues
[BOM: 524348|NSE : AARTIDRUGS]
| Y-o-Y | 9.14 % |
| 5 Yr CAGR | 14.85 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹2,716 Cr | 9.14 | |
| Mar2023 | ₹2,489 Cr | 15.49 | |
| Mar2022 | ₹2,155 Cr | 19.31 | |
| Mar2021 | ₹1,806 Cr | 15.71 | |
| Mar2020 | ₹1,561 Cr | - | |
AARTI DRUGS Operating Profit
[BOM: 524348|NSE : AARTIDRUGS]
| Y-o-Y | -6.96 % |
| 5 Yr CAGR | 10.06 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹309 Cr | -6.96 | |
| Mar2023 | ₹333 Cr | -24.47 | |
| Mar2022 | ₹440 Cr | 65.86 | |
| Mar2021 | ₹266 Cr | 25.89 | |
| Mar2020 | ₹211 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -14.75 % |
| 5 Yr CAGR | -4.18 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 11.39% | -14.75 | |
| Mar2023 | 13.36% | -34.64 | |
| Mar2022 | 20.44% | 39.05 | |
| Mar2021 | 14.7% | 8.81 | |
| Mar2020 | 13.51% | - | |
AARTI DRUGS Profit After Tax
[BOM: 524348|NSE : AARTIDRUGS]
| Y-o-Y | -18.89 % |
| 5 Yr CAGR | 16.67 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹166 Cr | -18.89 | |
| Mar2023 | ₹205 Cr | -26.88 | |
| Mar2022 | ₹280 Cr | 98.31 | |
| Mar2021 | ₹141 Cr | 57.55 | |
| Mar2020 | ₹90 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 10.95 % |
| 5 Yr CAGR | -3.50 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | 6.79 % | 10.95 | |
| Mar2023 | 6.12 % | -25.73 | |
| Mar2022 | 8.24 % | -36.66 | |
| Mar2021 | 13.01 % | 66.16 | |
| Mar2020 | 7.83 % | - | |
AARTI DRUGS Earnings Per Share (EPS)
[BOM: 524348|NSE : AARTIDRUGS]
| Y-o-Y | 3.84 % |
| 5 Yr CAGR | -25.55 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹19 | 3.84 | |
| Mar2023 | ₹18 | -18.88 | |
| Mar2022 | ₹22 | -26.42 | |
| Mar2021 | ₹30 | -50.42 | |
| Mar2020 | ₹61 | - | |
AARTI DRUGS Return on Capital Employed (ROCE)
[BOM: 524348|NSE : AARTIDRUGS]
| Y-o-Y | -3.10 % |
| 5 Yr CAGR | -8.47 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | 15.01% | -3.10 | |
| Mar2023 | 15.49% | -25.35 | |
| Mar2022 | 20.75% | -39.89 | |
| Mar2021 | 34.52% | 61.38 | |
| Mar2020 | 21.39% | - | |
AARTI DRUGS Share Price vs Sensex
| Current Share Price | : | ₹418.2 |
| Current MarketCap | : | ₹ 3,817.7 Cr |
| Updated EOD on | : | May 09,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| AARTI DRUGS | 17.6% |
25.6% |
-14.9% |
| SENSEX | -1.3% |
4.1% |
7.6% |
AARTI DRUGS related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
| BSE SMALLCAP | -1.3% | -1.6% | -1% |
| BSE HEALTHCARE | -1.8% | -1.6% | 15.9% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY MICROCAP 250 | -0.9% | -2.2% | -0.7% |
| NIFTY TOTAL MARKET | -1.5% | 1.9% | 3.3% |
You may also like the below Video Courses
FAQ about AARTI DRUGS Financials
How the annual revenues of AARTI DRUGS have changed ?
The Revenues of AARTI DRUGS have increased by 9.14% YoY .
How the Earnings per Share (EPS) of AARTI DRUGS have changed?
The Earnings Per Share (EPS) of AARTI DRUGS has increased by 3.84 % YoY .
Check out Intrinsic Value of Peers of AARTI DRUGS
Compare Stock Analytics of Peers of AARTI DRUGS
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
